Contact us
EN
FR
About
us
Our history
Expertise
Management
Board of directors
Rare diseases policy
Transparency
Pioneering
Science
Concept
Pipeline
Clinical
programs
MPS IIIA
GM1 gangliosidosis
Patients and
families
MPS IIIA
GM1 gangliosidosis
Links and resources
Partnering
Investors
Welcome
Stock Information
Press Releases
Events
AMF Regulated Information
Annual General Assembly 2017
Annual General Assembly 2018
Investor Contacts
Media
Home
> Press Releases
Press Releases
Latest tweet
First patient has been dosed in AAVance, a global Phase 2-3 clinical trial of LYS-SAF302, a gene therapy for the tr… https://t.co/8T7Gr89Atr
arrow-left
arrow-right
calendar
contact
download
facebook
linkedin
location
play
reset
rss
twitter
youtube
